The new version of the national drug insurance catalogue will be implemented today, with 91 new drugs added, including 26 drugs for the treatment of tumors.
On January 1, 2025, the new version of the national medical insurance drug catalogue will be officially implemented.
According to information previously released by the National Healthcare Security Administration, after adjustment, the “National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Directory (2024)” (hereinafter referred to as the “new national medical insurance drug catalog”), 91 new drugs have been added, while 43 drugs that have been replaced in clinical practice or have long been unavailable for supply will be removed.
Among the 91 newly added drugs, there are 26 drugs for tumors (including 4 for rare diseases), 15 drugs for chronic diseases such as diabetes (including 2 for rare diseases), 13 drugs for rare diseases, 7 anti-infection drugs, 11 Chinese patent medicines, 4 drugs for mental illness, and 21 drugs for other fields.
Huang Xinyu, Director of the Pharmaceutical Management Department of the National Healthcare Security Administration, revealed at a press conference that 90 of the newly added drugs are new varieties launched within 5 years, including 38 “world-new” innovative drugs.
After adjustment, the total number of drugs in the national medical insurance drug catalog has increased to 3159, including 1765 western medicines and 1394 Chinese patent medicines. The level of security in fields such as tumors, chronic diseases, rare diseases, and children’s medication has been significantly improved.
Huang Xinyu introduced that according to the new national medical insurance drug catalog, combined with negotiation and price reduction and medical insurance reimbursement factors, it is expected to reduce the burden on patients by more than 50 billion yuan in 2025.
